BioGaia (BIOG) Q2 2024 earnings summary

Executive summary

• Q2 2024 sales reached SEK 384 million, up 22% year-over-year, driven by strong growth in Asia-Pacific (49%) and Americas (22%), with Pediatrics leading.

• EBIT grew 42% to SEK 135 million, with EBIT margin improving to 35% from 30%.

• Direct business model expanded to Australia and New Zealand, now covering eight markets.

• Arbitration won with former Italian distributor; new exclusive distribution agreement signed with Recordati for Italy, Spain, and Portugal.

• Investments to support growth will add SEK 75–85 million in costs in H2 2024.

Financial highlights

• Q2 revenue: SEK 384 million (+22% year-over-year); EBIT: SEK 135 million (+42%); EBIT margin 35%.

• Gross margin improved to 74% from 72% last year.

• Earnings per share: SEK 1.10 (up from 0.80); profit after tax: SEK 111 million (+38%).

• Operating cash flow: SEK 119 million (+14%).

• Cash at period end: SEK 1,008 million.

Outlook and guidance

• Projecting SEK 75–85 million in additional costs in H2 2024 for investments in marketing, sales, and R&D.

• No specific sales growth guidance, but continued above-market growth targeted; returns from investments expected over the next year.

• Committed to long-term EBIT margin target (at least 34–44%), but timing to achieve this remains uncertain.

• Positive outlook based on innovative product portfolio, strong brand, and broad distribution network.